Today, Regeneron Pharmaceuticals Inc. (REGN) Position Held by Gulf International Bank UK Ltd

Today, Regeneron Pharmaceuticals Inc. (REGN) Position Held by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd continued to hold its position in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,195 shares of the biopharmaceutical company’s stock at the end of the third quarter. Gulf International Bank UK Ltd’s holdings in Regeneron Pharmaceuticals were worth $9,324,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares during the last quarter. Capital World Investors boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares during the last quarter. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in shares of Regeneron Pharmaceuticals by 0.6% in the second quarter. BlackRock Fund Advisors now owns 2,221,959 shares of the biopharmaceutical company’s stock worth $775,975,000 after buying an additional 13,282 shares during the last quarter. Institutional investors own 68.26% of the company’s stock.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.95% during mid-day trading on Monday, reaching $390.38. The company had a trading volume of 717,348 shares. Regeneron Pharmaceuticals Inc. has a 1-year low of $325.35 and a 1-year high of $566.52. The company has a market capitalization of $40.92 billion, a PE ratio of 56.96 and a beta of 1.79. The stock’s 50-day moving average price is $381.52 and its 200 day moving average price is $389.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.73 by $0.40. The business earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The business’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the company posted $3.47 EPS. Equities analysts expect that Regeneron Pharmaceuticals Inc. will post $11.73 EPS for the current year.

A number of equities analysts recently issued reports on REGN shares. Robert W. Baird reiterated a “neutral” rating and issued a $448.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 23rd. Goldman Sachs Group Inc. restated a “buy” rating and set a $521.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 27th. JPMorgan Chase & Co. set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, November 6th. Vetr cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $473.05 target price on the stock. in a research note on Monday, August 15th. Finally, Cowen and Company set a $430.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, November 6th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $468.87.

In related news, Director Arthur F. Ryan sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total transaction of $858,680.00. Following the completion of the sale, the director now directly owns 36,500 shares in the company, valued at $15,670,910. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $450.00, for a total value of $956,250.00. Following the sale, the director now owns 15,125 shares of the company’s stock, valued at $6,806,250. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Related posts

Leave a Comment